Cancer Genetics, Inc. Announces Participation at the 19th Annual Rodman and Renshaw Global Investment Conference in New York City September 10-12, 2017
Published on: Friday, September 8th, 2017 View all Media
RUTHERFORD, N.J., September 8, 2017 — Cancer Genetics, Inc. (Nasdaq: CGIX, the Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Panna Sharma, CEO and President of CGI, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
19th Annual Rodman & Renshaw Global Investment Conference – Cancer Genetics, Inc. Presentation
Date: Monday, September 11, 2017
Time: 3:25 pm Eastern Time
Location: Kennedy Room; Lotte New York Palace Hotel in New York City
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.